Scafring following wounding is a major medical problem. In skin wounds or bums scarring often leads to adverse cosmesis and consequent psychological problems, adverse function particularly over joints and retardation of growth especially in children. Scarring in muscle adversely affects movement and can cause ankylosis. In abdominal and pelvic organs scarring can lead to life threatening strictures and adhesions. In the eye, scarring can cause blindness, whilst in the central nervous system scarring inhibits neuronal reconnection and hence restoration of neuronal function. In almost every organ and tissue, scarring following injury or trauma is a major problem, for which there are no good preventative or therapeutic regimens.
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Several years ago, we and other researchers observed that skin wounds made in early embryos/fetuses of reptilian, avian and mammalian species healed without scarring. My laboratory subsequently embarked upon a detailed analysis of the cellular and molecular basis of scar-free healing in embryos compared to scar forming healing in adults. Investigations using embryonic and fetal mice revealed that incisional wounds made in embryos and fetuses, up to approximately the first half or 2/3 of gestation, healed without scarring. Wounds made during the last trimester of pregnancy or in early postnatal life showed progressively worse scarring. Thus, there is a temporal cut off for scar-free healing during late embryonic or early fetal life.
The phenomenon of scar-free embryonic healing does not depend on the special intra uterine environment e.g. warm, sterile, uniform 37°C, bathed in the amnoitic fluid. At least two lines of experimentation indicate that the fetal environment is unimportant for scar-free healing. First, adult skin grafted onto a fetus and subsequently wounded heals with a scar, whereas corresponding control fetal grafts heal without scarring. Conversely, embryonic skin grafted into subcutaneous locations in the adult heals without scarring. Second, experimentation on new born marsupials indicated that incisional wounds made within the first four days of the embryo attaching to the nipple on the marsupial, heal without scarring. The new born marsupials are not bathed in aminiotic fluid, are frequently in a microbiologically rich environment (from maternal faeces and urine) but like the late embryo or early fetus, have a very poorly developed immune system, however unlike the eutherian embryo or fetus, they have highly differentiated skin.
There are many cellular and molecular differences between scar-free embryonic healing and scar forming adult healing. One critical difference is the inflammatory response. Embryos mount a poor inflammatory response to wounding with the recruitment of only small inflammatory cells e.g. monocytes and macrophages to the wound site and even smaller numbers of mature activated cells. Consequently, the types and quantities of growth factors present in the embryonic wound compared to the adult wound are quite different. Embryonic wounds have a very low levels, for example, of transforming growth factors beta-I and beta-2 whereas adult wounds have a very high early levels of TGFB1 and TGFB2 (released from degranulating platelets and subsequently from recruited monocytes and macrophages).
Using the information gleaned from these molecular and cellular investigations comparing scar-free embryonic healing and scar forming adult healing, we have experimentally manipulated adult rodent, porcine and human wounds in an attempt to ameliorate or prevent scarring.
In the first series of experiments, we demonstrated that neutralising antibodies to transforming growth factor beta-i and beta-2 (TGFB1 and TGFB2) injected intradermally at the wound site could prevent subsequent scarring. Dose response and time response experiments showed that the neutralising antibodies had to be applied immediately before, at the time of, or immediately after wounding to achieve maximum effect. In fact the timing of any scar preventing therapy is critical. The best results are obtained if the therapy is applied before, at the time of, or immediately after wounding. This is a real biological phenomenon. All growth factors such as TGFB1 and TGFB2 operate as auto inductive cascades. A small initial amount of TGFB1 released from degranulating platelets is chemotactic to monocytes and macrophages which migrate to the wound site and secrete further TGFB1 and 2. TGFB1 is also autocatalytic, binding it to its own promoter and upregulating its own synthesis. There, thus exists a large amplification cascade. Consequently, neutralisation of a small amount of the growth factor early in the wound healing process leads to major effects later on. Moreover, in the early phases of wound healing, many key processes are regulated by a small number of growth factors, such as those released from degranulating platelets. However, within a few days of wounding, complex interacting networks of cytokine responses are established, such that it is much more diffilcult to obtain effects out of manipulating one or two cytokines: effects that can be produced early in the wound healing response before the interacting redundant cascades become established.
Neutralising antibodies to TGFB1 and TGFB2 markedly decrease scarring, such that there is no microscopic evidence of where the incisional wound was made and the dermal architecture is restituted to a normal basket weave pattern. Neutralising antibody therapy also reduces the number of monocytes and macrophages at the wound site, decreases the numbers of blood vessels and also decreases the early wound fibronectin content: effects which are consistent with low levels of transforming growth factor beta-i and beta-2. By using isoform specific antibodies, we have determined that neutralisation of transforming growth factors beta-i and beta-2 is required to give optimal anti-scarring effects. Neutralisation of TGFB3 has no anti-scarring effect at best and makes the scar worse in some instances. Conversely, addition of exogenous TGFB3 at the time of, or immediately after, wounding results in a marked improvement in scarring. It is therefore the ratio between TGFB3 on the one hand and TGFB 1 and TGFB2 on the other which is important for scar formation. Decreasing the levels of TGFB1 and TGFB2 relative to TGFB3 appears to be the key to the anti-scarring therapy. This conclusion is supported by wound healing studies in transgenic mice, which either under or over-express TGFB1 or TGFB3. Antisense oligonucleotides to TGFB1 and TGFB2 administered before wounding also prevent subsequent scarring. For the antisense oligonucleotide therapy it is essential to deliver the antisense oligonucleotides before wounding and therefore this therapy is only applicable to elective surgery (the most common form of trauma). The antisense oligonuclcotide technology takes advantage of the transient permeabilisation of cells which occurs during wounding to achieve very high loading of the antisense oligonucleotides into target cells.
These studies have led to new therapeutic regimes which have been tested in experimental rodents and pigs and are now entering human clinical trial.
Reagents in human clinical trial for anti-scarring e.g. in the central nervous system, the eye or the skin, currently include recombinant human phage neutralising antibodies to TGFB2 and TGFB1, antisense oligonucleotides to TGFB1 and 2, TGFB3 and plasmids expressing TGFB3 for gene therapy.
Transforming growth factor beta family members like most growth factors, are made as an inactive precursor. This precursor is subsequently activated by proteolytic cleavage to produce the active growth factor. Activation is therefore a key biological regulatory step. In the case of TGFB1, it is initially secreted as an inactive precursor associated with a larger protein transcribed from the same gene entitled 'the latency associated protein' (LAP). This LAP has three carbohydrate chains on two of which the terminal residues are the sugar Mannose-6-Phosphate. Activation of transfonrning growth factor beta is complex but depends in part on bonding of the Mannose-6-Phosphate /TGF-2 receptor, followed by a conformational change in the molecule, exposure of a protease sensitive site and cleavage of the active TGFB1 from the inactive LAP precurser. We have demonstrated that exogenous administration of Mannose-6-Phosphate can competitively inhibit binding of the TGFB latency associated peptide at the Mannose-6-Phosphate receptor, thus preventing activation of TGFB1 and hence inhibit scarring. The mode of delivery of the Mannose-6-Phosphate is crucial as the molecule is rapidly metabolised and appropriate vehicles have to be used to achieve the requisit tissue levels over the post-wounding period. However, single applications of Mannose-6-Phosphate in an appropriate vehicle at the time of wounding can markedly prevent scarring. These applications also reduce the number of monocytes and macrophages, blood vessels and early fibronectin content of the wounds similar to the effects seen with neutralising antibodies to TGFB1 and TGFB2. Mannose-6-Phosphate as an anti-scarring agent is currently in human clinical trial.
Manipulation of the levels of other growth factors, such as platelet derived growth factor and several interleukins early in the wound healing cascade can also have a scar modulating effect.
In parallel with the development of these novel antiscarring therapies, we have also devised both clinical and histological quantitative scales for the assessment of scarring. These scales include validated visual analogue scales for the assessment of the macroscopic features of scarring, together with similar scales for the assessment of histological scarring and the development of three dimensional image analysis to quantitate changes in the structure of the dermis in man and animals.
Interestingly, our studies of ageing rodents and humans have demonstrated that the maximum inflammatory response and hence cytokine profile is present in young adults who scar worst. Conversely, in old age, the inflammatory response is reduced. The growth factor profile differs both quantitatively and qualitatively (with decreased levels of TGFB1 and TGFB2 and increased levels of TGFB3) and the quality of scarring is markedly improved. There are major differences in healing speeds and quality between males and females with age and between pre and postmenopausal females, indicating the importance of the hormonal milieu.
We hypothesise that acute wounds are phylogenetically optimised for speed of healing under dirty conditions. The evolutionary response is to maximise the inflammatory response and put into overdrive the cytokine cascade. This ensures that the wound heals very quickly and has multiple redundant mechanisms. This is doubtless important to prevent further bleeding from minor trauma or septicaemia from a slowly healing wound. However, this massive inflammatory response swamps out the endogenous regenerative capacity of the dermis and results in scarring. With contemporary hygiene, we can modulate this early cytokine profile, changing the ratios of various growth factors and cytokines. Such manipulated wounds heal just as quickly with no evident signs of infection but with markedly improved scarring. Such studies indicate that there is a wide therapeutic window for the control of scarring in man, as this is something which evolution has not optimised. Interestingly, similar mechanisms appear to operate in chronic fibrotic disorders, such as pulmonary fibrosis, liver cirrhosis, glomerular nephritis, indicating that fundamental investigations of the basis of dermal scarring and how it might be prevented may have a more widespread application in many common human fibrotic disorders. scarring in adult wounds by neutralising antibodies to transforming growth factor beta (TGFB) Lancet, 1992; 339: 213-214 
